Samaritan gets grant for Alzheimer's blood test
This article was originally published in Clinica
Samaritan Pharmaceuticals and Georgetown University, are to develop a simple blood test for predicting Alzheimer's disease using a $188,000 grant from the US National Institutes of Health. The test will be based on detecting the detecting the increase of the hormone dehydroepiandrosterone (DHEA). Researchers from the Las Vegas, Nevada firm's Samaritan Research Laboratories, at Georgetown University, recently discovered a potential correlation between DHEA precursor levels in blood plasma, and Alzheimer's disease. Using the new funds, researchers plan to differentiate between the levels of DHEA precursor in the plasma of patients with and without the disease, and to define the relationship between the levels of DHEA precursor, in plasma, and Alzheimer's.
You may also be interested in...
China's centralized procurement scheme, if further expanded after causing the prices of 32 drugs to be cut by more than half in the latest round, will leave companies no room to breathe easy amid the already devastating coronavirus outbreak, analysts say.
Sangamo licensed Biogen zinc finger protein transcription factor candidates in an alliance worth over $2bn. Exercising an option it gained in 2017, Takeda bought celiac disease-focused PvP Biologics for up to $330m in earn-outs. A strong showing of IPOs prompted biopharma financing to increase from last month.
With many non-CE marked products being allowed onto various EU member state markets, who is going to monitor compliance? TÜV-SÜD’s Bassil Akra calls for cooperation to avoid unsafe products being used on patients.